Helsinn announces abstract accepted for oral presentation at the EORTC Cutaneous Lymphoma Meeting 2019
26 sept. 2019 06h35 HE
|
Helsinn Healthcare S.A.
Helsinn announces abstract accepted for oral presentation at the EORTC Cutaneous Lymphoma Meeting 2019 Lugano, Switzerland, September 26, 2019 – Helsinn, the Swiss pharmaceutical group focused on...
Helsinn and Recordati Rare Diseases to announce satellite symposium on advances in Mycosis Fungoides-Cutaneous T cell Lymphoma
19 sept. 2019 04h00 HE
|
Helsinn Healthcare S.A.
Helsinn and Recordati Rare Diseases to announce satellite symposium on advances in Mycosis Fungoides-Cutaneous T cell Lymphoma (MF-CTCL) treatment at the 49th European Society for Dermatological...
Helsinn and Lyfebulb Announce Call for Applications for Third Annual Patient-Driven Innovation Summit & Award in Oncology
17 sept. 2019 08h10 HE
|
Helsinn Healthcare S.A.
Helsinn and Lyfebulb Announce Call for Applications for Third Annual Patient-Driven Innovation Summit & Award in Oncology The Award recognizes Patient Entrepreneurs demonstrating...
Helsinn and Lyfebulb Announce Third Annual Patient-Driven Innovation Summit & Award in Oncology to be held during the 14th Monaco Biennale of Oncology 2020
29 août 2019 08h00 HE
|
Helsinn Healthcare S.A.
Helsinn and Lyfebulb Announce Third Annual Patient-Driven Innovation Summit & Award in Oncology to be held during the 14th Monaco Biennale of Oncology 2020 The Award recognizes Patient...
Helsinn and Endo Announce Agreement for Paladin Labs Inc. to Commercialize Pracinostat in Canada
31 juil. 2019 08h10 HE
|
Helsinn Healthcare S.A.
Helsinn and Endo Announce Agreement for Paladin Labs Inc. to Commercialize Pracinostat in Canada DUBLIN and LUGANO, July 31, 2019 -- Endo International plc (NASDAQ: ENDP), and Helsinn, a Swiss...
Helsinn Investment Fund Announces First Exit
15 juil. 2019 10h05 HE
|
Helsinn Healthcare S.A.
Helsinn Investment Fund Announces First Exit Luxembourg, July 15, 2019 – Helsinn Investment Fund S.A, SICAR, a fund focused on early-stage investment opportunities in areas of high unmet patient...
Helsinn appoints Giorgio Calderari, Group General Manager and Chief Operating Officer, to the Board of Directors
26 juin 2019 01h00 HE
|
Helsinn Healthcare S.A.
Helsinn appoints Giorgio Calderari, Group General Manager and Chief Operating Officer, to the Board of Directors Lugano, Switzerland, June 26, 2019: Helsinn, the Swiss pharmaceutical group focused on...
Helsinn to co-support a satellite symposium on current and emerging treatments of Acute Myeloid Leukemia (AML) at 24th European Hematology Association (EHA) Congress
12 juin 2019 03h30 HE
|
Helsinn Healthcare S.A.
Helsinn to co-support a satellite symposium on current and emerging treatments of Acute Myeloid Leukemia (AML) at 24th European Hematology Association (EHA) Congress Symposium will explore the...
Helsinn Group supports two events with the International Society for Cutaneous Lymphomas (ISCL) at the 24th World Congress of Dermatology
07 juin 2019 03h00 HE
|
Helsinn Healthcare S.A.
Helsinn Group supports two events with the International Society for Cutaneous Lymphomas (ISCL) at the 24th World Congress of Dermatology Cutaneous Lymphoma Meeting will update on latest developments...
Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Dr. Allison Barz Leahy, MD, University of Pennsylvania
01 juin 2019 08h00 HE
|
Helsinn Healthcare S.A.
Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Dr. Allison Barz Leahy, MD, University of Pennsylvania ...